COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
24/02/2026
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophy HOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in [...]
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
24/02/2026
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting [...]
Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics
24/02/2026
New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
24/02/2026
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution SAN [...]
Dentsply Sirona and Burkhart Dental Supply Announce Expanded Distribution Partnership to Include Dental Technology Equipment
24/02/2026
As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership [...]
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
24/02/2026
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical- [...]
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
24/02/2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the [...]
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
24/02/2026
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced [...]
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
24/02/2026
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo [...]
TAP Sleep Care Groundbreaking Dual Therapy: Mouth Shield + TAP Improves Oral, Cardiac, and Cognitive Health in OSA
24/02/2026
DALLAS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- TAP Sleep Care , powered by Airway Management, today highlights groundbreaking clinical research on the benefits of dual therapy using the patented Mouth Shield with TAP devices [...]
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
24/02/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A’TOMIC™ Nitinol Fixation System to the Smith+Nephew [...]
Centre for Neuro Skills Physician-Researcher Dr. Brent Masel to Receive NABIS Legends Award for Lifetime of Contributions to Traumatic Brain Injury Care
24/02/2026
North American Brain Injury Society honors the pioneering neurorehabilitation researcher and clinician at the NABIS 18th Annual Conference on Brain Injury, March 11–13, 2026, Hilton Arlington National Landing, Arlington [...]
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
24/02/2026
SAN FRANCISCO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track [...]
Respiree Strengthens Series A Syndicate to Advance Next-Generation Cardiorespiratory Care
24/02/2026
HOUSTON and SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Respiree , a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
24/02/2026
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par [...]
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
24/02/2026
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to [...]
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02/2026
Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files provisional patent [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24/02/2026
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating [...]

Pages